Literature DB >> 7801126

Fatty acylation of two internal lysine residues required for the toxic activity of Escherichia coli hemolysin.

P Stanley1, L C Packman, V Koronakis, C Hughes.   

Abstract

Hemolysin of Escherichia coli is activated by fatty acylation of the protoxin, directed by the putative acyl transferase HlyC and by acyl carrier protein (ACP). Mass spectrometry and Edman degradation of proteolytic products from mature toxin activated in vitro with tritium-labeled acylACP revealed two fatty-acylated internal lysine residues, lysine 564 and lysine 690. Resistance of the acylation to chemical treatments suggested that fatty acid was amide linked. Substitution of the two lysines confirmed that they were the only sites of acylation and showed that although each was acylated in the absence of the other, both sites were required for in vivo toxin activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7801126     DOI: 10.1126/science.7801126

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  51 in total

1.  Isolation and characterization of Escherichia coli tolC mutants defective in secreting enzymatically active alpha-hemolysin.

Authors:  H Vakharia; G J German; R Misra
Journal:  J Bacteriol       Date:  2001-12       Impact factor: 3.490

2.  Membrane interaction of Escherichia coli hemolysin: flotation and insertion-dependent labeling by phospholipid vesicles.

Authors:  C Hyland; L Vuillard; C Hughes; V Koronakis
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

3.  Purification and characterization of a hemolysin-like protein, Sll1951, a nontoxic member of the RTX protein family from the Cyanobacterium Synechocystis sp. strain PCC 6803.

Authors:  Tetsushi Sakiyama; Hironori Ueno; Hideya Homma; Osamu Numata; Tomohiko Kuwabara
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

4.  Mutations in HlyD, part of the type 1 translocator for hemolysin secretion, affect the folding of the secreted toxin.

Authors:  A L Pimenta; K Racher; L Jamieson; M A Blight; I B Holland
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

5.  Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.

Authors:  Mark A Smith; Rebecca A Weingarten; Lisa M Russo; Christy L Ventura; Alison D O'Brien
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

6.  Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder.

Authors:  Tamako A Garcia; Christy L Ventura; Mark A Smith; D Scott Merrell; Alison D O'Brien
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

7.  Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.

Authors:  T G Gleason; C W Houlgrave; A K May; T D Crabtree; R G Sawyer; W Denham; J G Norman; T L Pruett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 8.  Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.

Authors:  Eric Krueger; Angela C Brown
Journal:  Mol Oral Microbiol       Date:  2020-03-10       Impact factor: 3.563

Review 9.  The RTX pore-forming toxin α-hemolysin of uropathogenic Escherichia coli: progress and perspectives.

Authors:  Travis J Wiles; Matthew A Mulvey
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

10.  Acyltransferase-mediated selection of the length of the fatty acyl chain and of the acylation site governs activation of bacterial RTX toxins.

Authors:  Adriana Osickova; Humaira Khaliq; Jiri Masin; David Jurnecka; Anna Sukova; Radovan Fiser; Jana Holubova; Ondrej Stanek; Peter Sebo; Radim Osicka
Journal:  J Biol Chem       Date:  2020-05-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.